---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-241844"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:40:17.480072+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galera Therapeutics receives Nasdaq delisting notice for MVPHS non-compliance

## Summary
- Nasdaq notified Galera on Sep 25, 2023 that MVPHS fell below $15M required for Global Market listing.
- Company has 180 days, until March 25, 2024, to regain compliance by closing at $15M+ for 10 consecutive days.
- May consider transferring to Nasdaq Capital Market if compliance cannot be met on Global Market.
- Stock continues to trade under GRTX on Nasdaq Global Market; delisting risk if not cured by Compliance Date.
- No assurance that compliance will be regained or that an appeal would succeed if delisting proceeds.

## SEC filing metadata
- accession: 0001193125-23-241844
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312523241844/0001193125-23-241844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312523241844/d514868d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-241844
- JSON: https://secwatch.observer/filing/0001193125-23-241844.json
- Plain text: https://secwatch.observer/filing/0001193125-23-241844.txt

## Key facts
- Listing & Compliance Notices
  Galera Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C)
  source text: September 25, 2023, Galera Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the Company is no longer in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock, par value $0.001 per share (“Common Stock”), which continues to trade on The Nasd
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312523241844/0001193125-23-241844-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.